The companies will use Somalogic's SomaScan proteomic platform to measure levels of as many as 5,000 proteins in up to 40,000 of DeCode's patient samples.
Syracuse University researchers have developed a nanopore-based technology that could enable detection of proteins in complex biological samples like serum.
Researchers have shown nanoparticles can enrich low molecular weight, low abundance plasma proteins that are hard to detect using standard proteomic workflows.
The company plans to use the funds to drive commercialization of its recently launched Fluidity One instrument and develop other products in its pipeline.
In PLOS this week: MYRF variant linked to congenital diaphragmatic hernia, analysis of the "dragon's blood" red resin produced by traditional medicine plants, and more.
